Platelets Journal Welcomes Sarah Westbury as Principal Editor to the Editorial Board
Platelets Journal shared a post on LinkedIn:
“We are delighted to welcome Sarah Westbury as a newly appointed Principal Editor to the Platelet editorial board!
Westbury is a Consultant Senior Lecturer in Haematology at the University of Bristol and a Consultant Haematologist at University Hospitals Bristol and Weston NHS Foundation Trust.
Westbury has extensive experience as a clinician and researcher investigating inherited haematological disorders, with a particular interest in rare diseases that perturb platelet number and function.
Explore some of Westbury’s recent collaborations published in Platelets below.”
Title: ACTN1 variants associated with thrombocytopenia
Authors: Sarah K. Westbury, Deborah K. Shoemark, Andrew D. Mumford
Read the Full Article on Platelets.
Title: TUBB1 variants and human platelet traits
Authors: Kate Burley, Sarah K Westbury, Andrew D Mumford
Read the Full Article on Platelets.
Title: FLNA variants associated with disorders of platelet number or function
Authors: Pietro Vassallo, Sarah K Westbury, Andrew D Mumford
Read the Full Article on Platelets.
Stay updated with Hemostasis Today.
-
Oct 17, 2026, 04:07Weihao Li: Global HEPATIC Registry Findings on Post-Transplant Arterial Thrombosis
-
Oct 17, 2026, 03:56Ghaith Abu-Zeinah: ASH Publishes 2026 Guidelines for Myelofibrosis Management in Blood Advances
-
Oct 17, 2026, 03:48Tristan Siokos: Why Vascular Occlusion Is More Than Just Clots – Breakdown of the 8 Pathways
-
Oct 17, 2026, 02:36Archil Jaliashvili: Oxygen Transport in Capillaries
-
Oct 17, 2026, 02:35Carly Newton: Understanding Access to Red Blood Cell Exchange for People Living With SCD
-
Oct 17, 2026, 02:34Raising Awareness of Blood Clots During and After Pregnancy – Thrombosis UK
-
Oct 17, 2026, 02:33Alaa Salamat: Our Research Accepted for Publication at ASH 2026
-
Oct 17, 2026, 02:32Mohammed Al Sharif: Discussing Factor XIII Testing and Its Clinical Significance
-
Oct 17, 2026, 02:31Joanna Popiolek-Kalisz: Talking about Novel Pharmacotherapy for Hypertension at CV Prevention and Intervention